3.4.22.52	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9296555&form=6&db=m	Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease.	causal interaction,ongoing research,unassigned	3,1,0	
3.4.22.52	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11516996&form=6&db=m	The calpain family and human disease.	causal interaction,diagnostic usage,unassigned	4,1,0	
3.4.22.52	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12070670&form=6&db=m	Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2.	causal interaction,diagnostic usage,ongoing research,therapeutic application	3,2,2,2	
3.4.22.52	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16150694&form=6&db=m	Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain.	unassigned	-	
3.4.22.52	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17157313&form=6&db=m	The crystal structures of human calpains 1 and 9 imply diverse mechanisms of action and auto-inhibition.	causal interaction,ongoing research,unassigned	1,3,0	
3.4.22.52	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18396356&form=6&db=m	Design and synthesis of calpain inhibitory 6-pyridone 2-carboxamide derivatives.	causal interaction,therapeutic application,unassigned	2,4,0	
3.4.22.52	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19041242&form=6&db=m	Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors.	causal interaction,therapeutic application,unassigned	2,4,0	
3.4.22.52	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23834438&form=6&db=m	Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors.	unassigned	-	
3.4.22.52	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25476568&form=6&db=m	Accumulation of ?-synuclein in dementia with Lewy bodies is associated with decline in the ?-synuclein-degrading enzymes kallikrein-6 and calpain-1.	diagnostic usage,ongoing research,unassigned	3,1,0	
3.4.22.52	Alzheimer Disease	http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25641096&form=6&db=m	Truncation and activation of GSK-3? by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease.	causal interaction,unassigned	3,0